-
STEP-HFpEF trial results show benefit of GLP-1 receptor agonists for patients with heart failure and diabetes
“Obesity is not just a comorbidity in people with heart failure with preserved ejection fraction but is a target for treatment,” said cardiac surgeon Subodh Verma, MD, PhD, FRCSC, one of the experts who will discuss new data from the STEP-HFpEF and STEP-HFpEF-DM trials.
-
Investigators to share results from Part 1 of CATALYST study of hypercortisolism in type 2 diabetes
Investigators including John B. Buse, MD, PhD, will present findings from a study of the prevalence of hypercortisolism in patients with an A1C of ≥7.5% despite receiving multiple standard-of-care therapies.
-
Investigators to discuss TIGHT study on in-patient CGM
TIGHT Study Chair Irl B. Hirsch, MD, and other researchers will share new data on whether continuous glucose monitoring (CGM) can be used as effectively in the hospital as it is in the outpatient setting. The study also highlighted the challenges created by a scarcity of dedicated in-hospital diabetes care teams in community hospitals.
-
Researchers to share early INHALE-3 data on efficacy of basal insulin plus inhaled insulin for type 1 diabetes
Investigators will discuss findings from a randomized trial that compared a regimen of basal insulin plus inhaled insulin and CGM versus usual care and CGM in adults with type 1 diabetes.
-
Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early
Diabetes is the leading cause of chronic kidney disease. Glucagon-like peptide-1 (GLP-1) receptor agonists hold promise as an effective new therapy to combat this condition. Richard E. Pratley, MD, and other researchers will share new data on the renal and cardiovascular benefits of GLP-1 receptor agonists.
-
SELECT trial demonstrates semaglutide benefits beyond reduction of cardiovascular events
Although SELECT was not designed as a diabetes prevention study, investigators have found clinical benefits for these patients. Using a glucagon-like peptide-1 (GLP-1) receptor agonist can reduce risk of progressing to diabetes, for example, said Steven E. Kahn, MB, ChB, one of the panelists in a symposium that will examine SELECT trial results.
-
ATTEMPT trial reveals SGLT2 inhibitors’ impact on adolescent and youth type 1 diabetes
Farid Mahmud, MD, will present the renal and glycemic outcomes from a trial designed to assess the impact of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in combination with insulin therapy. The session will include insights on adjunctive therapy in youth with type 1 diabetes and patient perspectives on disease management.